Antibody neutralization and escape by HIV-1

  • Nature volume 422, pages 307312 (20 March 2003)
  • doi:10.1038/nature01470
  • Download Citation


Neutralizing antibodies (Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear1,2,3,4,5,6. To gain a better understanding of this role, we examined plasma from patients with acute HIV infection. Here we report the detection of autologous Nab as early as 52 days after detection of HIV-specific antibodies. The viral inhibitory activity of Nab resulted in complete replacement of neutralization-sensitive virus by successive populations of resistant virus. Escape virus contained mutations in the env gene that were unexpectedly sparse, did not map generally to known neutralization epitopes, and involved primarily changes in N-linked glycosylation. This pattern of escape, and the exceptional density of HIV-1 envelope glycosylation generally7,8, led us to postulate an evolving ‘glycan shield’ mechanism of neutralization escape whereby selected changes in glycan packing prevent Nab binding but not receptor binding. Direct support for this model was obtained by mutational substitution showing that Nab-selected alterations in glycosylation conferred escape from both autologous antibody and epitope-specific monoclonal antibodies. The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire.

  • Subscribe to Nature for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107–112 (1990)

  2. 2.

    et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176, 924–932 (1997)

  3. 3.

    , , , & Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71, 3734–3741 (1997)

  4. 4.

    , , , & Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75, 10200–10207 (2001)

  5. 5.

    et al. Neutralizing antibodies have limited effects on the control of established HIV-1 in vivo. Immunity 10, 431–438 (1999)

  6. 6.

    , , & The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 (Suppl. A), S137–S162 (1999)

  7. 7.

    Kuiken, C. L. et al. (eds) Human Retroviruses and AIDS 2000: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, 2000)

  8. 8.

    & HIV glycosylation: What does it portend? AIDS Res. Hum. Retroviruses 8, 1459–1460 (1992)

  9. 9.

    et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354, 1782–1785 (1999)

  10. 10.

    et al. A novel antiviral intervention results in a more accurate assessment of HIV-1 replication dynamics and T-cell decay in vivo. J. Virol. (in the press)

  11. 11.

    et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995)

  12. 12.

    et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205–211 (1997)

  13. 13.

    et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896–1905 (2002)

  14. 14.

    et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8, 1329–1339 (2000)

  15. 15.

    et al. The antigenic structure of the human immunodeficiency virus gp120 envelope glycoprotein. Nature 393, 705–711 (1998)

  16. 16.

    & The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 280, 1884–1888 (1998)

  17. 17.

    , , & GP120: Biologic aspects of structural features. Annu. Rev. Immunol. 19, 253–274 (2001)

  18. 18.

    , , , & Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74, 1961–1972 (2000)

  19. 19.

    et al. Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J. Biol. Chem. 265, 8519–8524 (1990)

  20. 20.

    et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α → 2 mannose residues on the outer face of gp120. J. Virol. 76, 7306–7321 (2002)

  21. 21.

    et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293–7305 (2002)

  22. 22.

    et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76, 9035–9045 (2002)

  23. 23.

    , & Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75, 2041–2050 (2001)

  24. 24.

    , & Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71, 7719–7727 (1997)

  25. 25.

    et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431–438 (1994)

  26. 26.

    , & A role for carbohydrates in immune evasion in AIDS. Nature Med. 4, 679–684 (1998)

  27. 27.

    et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682 (2002)

  28. 28.

    , & Profile of a Quasispecies: The Selected Mutational Landscape of HIV and Influenza (Vrije Univ., Amsterdam, 1999)

  29. 29.

    & Viral Dynamics (Oxford Univ. Press, Oxford, 2000)

  30. 30.

    , , & Rapid evolution of the neutralizing antibody response to human immunodeficiency virus type 1 infection. Proc. Natl Acad. Sci. USA (in the press)

Download references


We thank S. Zolla-Pazner for HIV-1 V3 specific monoclonal antibodies; D. Burton, B. Korber, J. Mascola, D. Montefiore, J. Moore, L. Shapiro and R. Wyatt for discussions; S. Meleth for assistance with statistical analyses; and W. Abbott for artwork and technical assistance. This work was supported by the Acute Infection Early Disease Research Program of the National Institutes of Allergy and Infectious Diseases, the UAB Center for AIDS Research, the UAB General Clinical Research Center, and the National Institutes of Health. We also thank Bristol-Myers Squibb, GlaxoSmithKline, Agouron and Merck for continuing support of acute HIV-1 infection studies.

Author information


  1. *Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, KAUL 816, Birmingham, Alabama 35294-0024, USA

    • Xiping Wei
    • , Julie M. Decker
    • , Shuyi Wang
    •  & George M. Shaw
  2. †Department of Medicine, University of Alabama at Birmingham, 720 South 20th Street, KAUL 816, Birmingham, Alabama 35294-0024, USA

    • Huxiong Hui
    • , John C. Kappes
    • , Xiaoyun Wu
    • , Jesus F. Salazar-Gonzalez
    • , Maria G. Salazar
    • , J. Michael Kilby
    • , Michael S. Saag
    • , Beatrice H. Hahn
    •  & George M. Shaw
  3. ‡Department of Microbiology, University of Alabama at Birmingham, 720 South 20th Street, KAUL 816, Birmingham, Alabama 35294-0024, USA

    • John C. Kappes
    • , Beatrice H. Hahn
    •  & George M. Shaw
  4. §Institute for Advanced Study, Princeton, New Jersey 08540, USA

    • Natalia L. Komarova
    •  & Martin A. Nowak
  5. Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA

    • Peter D. Kwong


  1. Search for Xiping Wei in:

  2. Search for Julie M. Decker in:

  3. Search for Shuyi Wang in:

  4. Search for Huxiong Hui in:

  5. Search for John C. Kappes in:

  6. Search for Xiaoyun Wu in:

  7. Search for Jesus F. Salazar-Gonzalez in:

  8. Search for Maria G. Salazar in:

  9. Search for J. Michael Kilby in:

  10. Search for Michael S. Saag in:

  11. Search for Natalia L. Komarova in:

  12. Search for Martin A. Nowak in:

  13. Search for Beatrice H. Hahn in:

  14. Search for Peter D. Kwong in:

  15. Search for George M. Shaw in:

Competing interests

The authors declare that they have no competing financial interests.

Corresponding author

Correspondence to George M. Shaw.

Supplementary information


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.